Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New data reported for Qnexa in high cardiovascular risk type 2 diabetics

June 27, 2008

Melior and Pfizer sign option agreement for MLR-1023 for type 2 diabetes

June 27, 2008

European Commission approves extension of Amgen's marketing authorization for Mimpara

June 27, 2008

Abbott patents DGAT-1 inhibitors

June 26, 2008

Recent Santen patents describe novel agents for metabolic disorders

June 26, 2008

Albiglutide safe and well tolerated in early clinical studies

June 26, 2008

FDA approves PrandiMet, a repaglinide and metformin fixed-dose tablet

June 26, 2008

BioGeneriX and Neose initiate phase II GlycoPEG-GCSF trial

June 26, 2008

Akesis to initiate 13-week animal study for AKP- 020

June 26, 2008

Emisphere and Novo Nordisk to collaborate on development of oral GLP-1 receptor agonists

June 26, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...